Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

Overview

Journal Am J Respir Crit Care Med

Specialty Critical Care

Date 2023 Jun 26

PMID 37364283

Authors

Antonio Anzueto

Igor Z Barjaktarevic

Thomas M Siler

Tara Rheault

Thomas Bengtsson

Kathleen Rickard

Frank Sciurba

Affiliations

Soon will be listed here.

Abstract

Clinicaltrials: gov identifier NCT04542057, EudraCT identifier 2020-002069-32).

Citing Articles

Integrating green analytical chemistry and analytical quality by design: an innovative approach for RP-UPLC method development of ensifentrine in bulk and inhalation formulations.

Vanga M, Bukke S, Kusuma P, Narapureddy B, Thalluri C BMC Chem. 2025; 19(1):70.

PMID: 40089734 DOI: 10.1186/s13065-025-01448-8.

Molecular Approaches to Treating Chronic Obstructive Pulmonary Disease: Current Perspectives and Future Directions.

Vu S, Veit K, Sadikot R Int J Mol Sci. 2025; 26(5).

PMID: 40076807 PMC: 11899978. DOI: 10.3390/ijms26052184.

Targeting Non-Eosinophilic Immunological Pathways in COPD and AECOPD: Current Insights and Therapeutic Strategies.

Razia D, Gao C, Wang C, An Y, Wang F, Liu L Int J Chron Obstruct Pulmon Dis. 2025; 20:511-532.

PMID: 40066199 PMC: 11892741. DOI: 10.2147/COPD.S506616.

Phosphodiesterase 4 inhibition as a novel treatment for stroke.

Zhong J, Yu X, Lin Z PeerJ. 2025; 13:e18905.

PMID: 39897494 PMC: 11786714. DOI: 10.7717/peerj.18905.

Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies.

Dransfield M, Marchetti N, Kalhan R, Reyner D, Dixon A, Rheault T Chron Respir Dis. 2025; 22:14799731251314874.

PMID: 39854278 PMC: 11760128. DOI: 10.1177/14799731251314874.

References

Mahler D, Wells C . Evaluation of clinical methods for rating dyspnea. Chest. 1988; 93(3):580-6. DOI: 10.1378/chest.93.3.580. View

Stolz D, Mkorombindo T, Schumann D, Agusti A, Ash S, Bafadhel M . Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet. 2022; 400(10356):921-972. PMC: 11260396. DOI: 10.1016/S0140-6736(22)01273-9. View

Chen S, Small M, Lindner L, Xu X . Symptomatic burden of COPD for patients receiving dual or triple therapy. Int J Chron Obstruct Pulmon Dis. 2018; 13:1365-1376. PMC: 5927353. DOI: 10.2147/COPD.S163717. View

Zuo H, Cattani-Cavalieri I, Musheshe N, Nikolaev V, Schmidt M . Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacol Ther. 2019; 197:225-242. DOI: 10.1016/j.pharmthera.2019.02.002. View

Matera M, Cazzola M, Page C . Prospects for COPD treatment. Curr Opin Pharmacol. 2020; 56:74-84. DOI: 10.1016/j.coph.2020.11.003. View

Calverley P, Rabe K, Goehring U, Kristiansen S, Fabbri L, Martinez F . Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374(9691):685-94. DOI: 10.1016/S0140-6736(09)61255-1. View

Franciosi L, Diamant Z, Banner K, Zuiker R, Morelli N, Kamerling I . Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2014; 1(9):714-27. DOI: 10.1016/S2213-2600(13)70187-5. View

Quaderi S, Hurst J . The unmet global burden of COPD. Glob Health Epidemiol Genom. 2018; 3:e4. PMC: 5921960. DOI: 10.1017/gheg.2018.1. View

Boswell-Smith V, Spina D, Oxford A, Comer M, Seeds E, Page C . The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565.... J Pharmacol Exp Ther. 2006; 318(2):840-8. DOI: 10.1124/jpet.105.099192. View

10.

Schmidt D, Watson N, Dent G, Ruhlmann E, Branscheid D, Magnussen H . The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways. Br J Pharmacol. 2001; 131(8):1607-18. PMC: 1572487. DOI: 10.1038/sj.bjp.0703725. View

11.

Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-38. DOI: 10.1056/NEJMoa0909883. View

12.

Cazzola M, Rogliani P, Matera M . The future of bronchodilation: looking for new classes of bronchodilators. Eur Respir Rev. 2019; 28(154). PMC: 9488694. DOI: 10.1183/16000617.0095-2019. View

13.

Watz H, Rickard K, Rheault T, Bengtsson T, Singh D . Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis. Int J Chron Obstruct Pulmon Dis. 2020; 15:2199-2206. PMC: 7502392. DOI: 10.2147/COPD.S263025. View

14.

Calzetta L, Cazzola M, Page C, Rogliani P, Facciolo F, Matera M . Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm Pharmacol Ther. 2015; 32:15-23. DOI: 10.1016/j.pupt.2015.03.007. View

15.

Ferguson G, Kerwin E, Rheault T, Bengtsson T, Rickard K . A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy. Int J Chron Obstruct Pulmon Dis. 2021; 16:1137-1148. PMC: 8075181. DOI: 10.2147/COPD.S307160. View

16.

Nici L, Mammen M, Charbek E, Alexander P, Au D, Boyd C . Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020; 201(9):e56-e69. PMC: 7193862. DOI: 10.1164/rccm.202003-0625ST. View

17.

Anzueto A, Barjaktarevic I, Siler T, Rheault T, Bengtsson T, Rickard K . Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023; 208(4):406-416. PMC: 10449067. DOI: 10.1164/rccm.202306-0944OC. View

18.

Lipson D, Barnhart F, Brealey N, Brooks J, Criner G, Day N . Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018; 378(18):1671-1680. DOI: 10.1056/NEJMoa1713901. View

19.

Mahler D, Witek Jr T . The MCID of the transition dyspnea index is a total score of one unit. COPD. 2006; 2(1):99-103. DOI: 10.1081/copd-200050666. View

20.

Fabbri L, Calverley P, Izquierdo-Alonso J, Bundschuh D, Brose M, Martinez F . Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374(9691):695-703. DOI: 10.1016/S0140-6736(09)61252-6. View